Format
Sort by
Items per page

Send to

Choose Destination

Best matches for Själander A[au]:

Search results

Items: 1 to 50 of 68

1.

Direct comparisons of effectiveness and safety of treatment with Apixaban, Dabigatran and Rivaroxaban in atrial fibrillation.

Jansson M, Själander S, Sjögren V, Renlund H, Norrving B, Själander A.

Thromb Res. 2020 Jan;185:135-141. doi: 10.1016/j.thromres.2019.11.010. Epub 2019 Nov 13.

PMID:
31816553
2.

Increased Risk of Chronic Myeloid Leukemia Following Gastric Conditions Indicating Helicobacter pylori Infection: A Case-Control Study.

Larfors G, Richter J, Själander A, Stenke L, Höglund M.

Cancer Epidemiol Biomarkers Prev. 2020 Jan;29(1):151-156. doi: 10.1158/1055-9965.EPI-19-0758. Epub 2019 Oct 16.

PMID:
31619405
3.

Triple therapy after PCI - Warfarin treatment quality and bleeding risk.

Wadell D, Jensen J, Englund E, Själander A.

PLoS One. 2018 Dec 18;13(12):e0209187. doi: 10.1371/journal.pone.0209187. eCollection 2018.

4.

NOAK vid venös tromboembolism samt hantering av blödningar.

Själander S, Själander A.

Lakartidningen. 2018 Dec 4;115. pii: FAS3. Swedish. No abstract available.

5.

Predictors for INR-control in a well-managed warfarin treatment setting.

Björck F, Kadhim H, Själander A.

J Thromb Thrombolysis. 2019 Feb;47(2):227-232. doi: 10.1007/s11239-018-1765-4.

6.

Dabigatran, rivaroxaban and apixaban vs. high TTR warfarin in atrial fibrillation.

Själander S, Sjögren V, Renlund H, Norrving B, Själander A.

Thromb Res. 2018 Jul;167:113-118. doi: 10.1016/j.thromres.2018.05.022. Epub 2018 May 17.

PMID:
29803981
7.

Atherothrombosis and Thromboembolism: Position Paper from the Second Maastricht Consensus Conference on Thrombosis.

Spronk HMH, Padro T, Siland JE, Prochaska JH, Winters J, van der Wal AC, Posthuma JJ, Lowe G, d'Alessandro E, Wenzel P, Coenen DM, Reitsma PH, Ruf W, van Gorp RH, Koenen RR, Vajen T, Alshaikh NA, Wolberg AS, Macrae FL, Asquith N, Heemskerk J, Heinzmann A, Moorlag M, Mackman N, van der Meijden P, Meijers JCM, Heestermans M, Renné T, Dólleman S, Chayouâ W, Ariëns RAS, Baaten CC, Nagy M, Kuliopulos A, Posma JJ, Harrison P, Vries MJ, Crijns HJGM, Dudink EAMP, Buller HR, Henskens YMC, Själander A, Zwaveling S, Erküner O, Eikelboom JW, Gulpen A, Peeters FECM, Douxfils J, Olie RH, Baglin T, Leader A, Schotten U, Scaf B, van Beusekom HMM, Mosnier LO, van der Vorm L, Declerck P, Visser M, Dippel DWJ, Strijbis VJ, Pertiwi K, Ten Cate-Hoek AJ, Ten Cate H.

Thromb Haemost. 2018 Feb;118(2):229-250. doi: 10.1160/TH17-07-0492. Epub 2018 Jan 29.

8.

Ischemic stroke rates decline in patients with atrial fibrillation as anticoagulants uptake improves: A Swedish cohort study.

Mochalina N, Isma N, Svensson PJ, Själander A, Carlsson M, Juhlin T, Wieloch M.

Thromb Res. 2017 Oct;158:44-48. doi: 10.1016/j.thromres.2017.08.004. Epub 2017 Aug 11.

PMID:
28822239
9.

Non-vitamin K oral anticoagulants are non-inferior for stroke prevention but cause fewer major bleedings than well-managed warfarin: A retrospective register study.

Sjögren V, Byström B, Renlund H, Svensson PJ, Oldgren J, Norrving B, Själander A.

PLoS One. 2017 Jul 10;12(7):e0181000. doi: 10.1371/journal.pone.0181000. eCollection 2017.

10.

Safety and Efficacy of Bridging With Low-Molecular-Weight Heparin During Temporary Interruptions of Warfarin: A Register-Based Cohort Study.

Sjögren V, Grzymala-Lubanski B, Renlund H, Svensson PJ, Själander A.

Clin Appl Thromb Hemost. 2017 Nov;23(8):961-966. doi: 10.1177/1076029617706756. Epub 2017 May 4.

PMID:
28468510
11.

No increased prevalence of malignancies among first-degree relatives of 800 patients with chronic myeloid leukemia: a population-based study in Sweden.

Gunnarsson N, Höglund M, Stenke L, Sandin F, Björkholm M, Dreimane A, Lambe M, Markevärn B, Olsson-Strömberg U, Wadenvik H, Richter J, Själander A.

Leukemia. 2017 Aug;31(8):1825-1827. doi: 10.1038/leu.2017.131. Epub 2017 May 2. No abstract available.

12.

The impact of socio-economic factors on treatment choice and mortality in chronic myeloid leukaemia.

Larfors G, Sandin F, Richter J, Själander A, Stenke L, Lambe M, Höglund M.

Eur J Haematol. 2017 Apr;98(4):398-406. doi: 10.1111/ejh.12845. Epub 2017 Jan 16.

PMID:
28009456
13.

Assessment of Use vs Discontinuation of Oral Anticoagulation After Pulmonary Vein Isolation in Patients With Atrial Fibrillation.

Själander S, Holmqvist F, Smith JG, Platonov PG, Kesek M, Svensson PJ, Blomström-Lundqvist C, Tabrizi F, Tapanainen J, Poci D, Jönsson A, Själander A.

JAMA Cardiol. 2017 Feb 1;2(2):146-152. doi: 10.1001/jamacardio.2016.4179.

PMID:
27893055
14.

Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia.

Ilander M, Olsson-Strömberg U, Schlums H, Guilhot J, Brück O, Lähteenmäki H, Kasanen T, Koskenvesa P, Söderlund S, Höglund M, Markevärn B, Själander A, Lotfi K, Dreimane A, Lübking A, Holm E, Björeman M, Lehmann S, Stenke L, Ohm L, Gedde-Dahl T, Majeed W, Ehrencrona H, Koskela S, Saussele S, Mahon FX, Porkka K, Hjorth-Hansen H, Bryceson YT, Richter J, Mustjoki S.

Leukemia. 2017 May;31(5):1108-1116. doi: 10.1038/leu.2016.360. Epub 2016 Nov 28.

15.

Incidence and risk factors for thromboembolism and major bleeding in patients with mechanical valve prosthesis: A nationwide population-based study.

Labaf A, Svensson PJ, Renlund H, Jeppsson A, Själander A.

Am Heart J. 2016 Nov;181:1-9. doi: 10.1016/j.ahj.2016.06.026. Epub 2016 Aug 11.

PMID:
27823679
16.

Bleeding complications and mortality in warfarin-treated VTE patients, dependence of INR variability and iTTR.

Sandén P, Renlund H, Svensson PJ, Själander A.

Thromb Haemost. 2017 Jan 5;117(1):27-32. doi: 10.1160/TH16-06-0489. Epub 2016 Sep 22.

PMID:
27652593
17.

Warfarin treatment quality and prognosis in patients with mechanical heart valve prosthesis.

Grzymala-Lubanski B, Svensson PJ, Renlund H, Jeppsson A, Själander A.

Heart. 2017 Feb;103(3):198-203. doi: 10.1136/heartjnl-2016-309585. Epub 2016 Sep 2.

PMID:
27590664
18.

Warfarin persistence among atrial fibrillation patients - why is treatment ended?

Björck F, Ek A, Johansson L, Själander A.

Cardiovasc Ther. 2016 Dec;34(6):468-474. doi: 10.1111/1755-5922.12224.

PMID:
27565120
19.

Venous thromboembolism and cancer risk.

Sandén P, Svensson PJ, Själander A.

J Thromb Thrombolysis. 2017 Jan;43(1):68-73. doi: 10.1007/s11239-016-1411-y.

20.

Outcomes in a Warfarin-Treated Population With Atrial Fibrillation.

Björck F, Renlund H, Lip GY, Wester P, Svensson PJ, Själander A.

JAMA Cardiol. 2016 May 1;1(2):172-80. doi: 10.1001/jamacardio.2016.0199.

PMID:
27437888
21.

Advanced phase chronic myeloid leukaemia (CML) in the tyrosine kinase inhibitor era - a report from the Swedish CML register.

Söderlund S, Dahlén T, Sandin F, Olsson-Strömberg U, Creignou M, Dreimane A, Lübking A, Markevärn B, Själander A, Wadenvik H, Stenke L, Richter J, Höglund M.

Eur J Haematol. 2017 Jan;98(1):57-66. doi: 10.1111/ejh.12785. Epub 2016 Aug 19.

PMID:
27428357
22.

Cardiovascular Events Associated With Use of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: A Population-Based Cohort Study.

Dahlén T, Edgren G, Lambe M, Höglund M, Björkholm M, Sandin F, Själander A, Richter J, Olsson-Strömberg U, Ohm L, Bäck M, Stenke L; Swedish CML Group and the Swedish CML Register Group.

Ann Intern Med. 2016 Aug 2;165(3):161-6. doi: 10.7326/M15-2306. Epub 2016 Jun 14.

PMID:
27295519
23.

Increased prevalence of prior malignancies and autoimmune diseases in patients diagnosed with chronic myeloid leukemia.

Gunnarsson N, Höglund M, Stenke L, Wållberg-Jonsson S, Sandin F, Björkholm M, Dreimane A, Lambe M, Markevärn B, Olsson-Strömberg U, Wadenvik H, Richter J, Själander A.

Leukemia. 2016 Jul;30(7):1562-7. doi: 10.1038/leu.2016.59. Epub 2016 Mar 8.

PMID:
27080811
24.

Antithrombotic therapy in patients with non-valvular atrial fibrillation in Southern Sweden: A population-based cohort study.

Mochalina N, Jöud A, Carlsson M, Sandberg MEC, Själander A, Juhlin T, Svensson PJ.

Thromb Res. 2016 Apr;140:94-99. doi: 10.1016/j.thromres.2016.02.023. Epub 2016 Feb 23.

PMID:
26938155
25.

Population-based assessment of chronic myeloid leukemia in Sweden: striking increase in survival and prevalence.

Gunnarsson N, Sandin F, Höglund M, Stenke L, Björkholm M, Lambe M, Olsson-Strömberg U, Richter J, Själander A.

Eur J Haematol. 2016 Oct;97(4):387-92. doi: 10.1111/ejh.12743. Epub 2016 Feb 26.

PMID:
26833713
26.

Bleeding complications in venous thrombosis patients on well-managed warfarin.

Sandén P, Renlund H, Svensson PJ, Själander A.

J Thromb Thrombolysis. 2016 Feb;41(2):351-8. doi: 10.1007/s11239-015-1305-4.

PMID:
26660340
27.

INR variability and outcomes in patients with mechanical heart valve prosthesis.

Labaf A, Själander A, Stagmo M, Svensson PJ.

Thromb Res. 2015 Dec;136(6):1211-5. doi: 10.1016/j.thromres.2015.10.044. Epub 2015 Oct 31.

PMID:
26558830
28.

Warfarin treatment complications do not correlate to cTTR when above 70.

Sandén P, Renlund H, Svensson PJ, Själander A.

Thromb Res. 2015 Dec;136(6):1185-9. doi: 10.1016/j.thromres.2015.10.031. Epub 2015 Oct 19.

PMID:
26508465
29.

Glomerular filtration rate and association to stroke, major bleeding, and death in patients with mechanical heart valve prosthesis.

Labaf A, Grzymala-Lubanski B, Själander A, Svensson PJ, Stagmo M.

Am Heart J. 2015 Sep;170(3):559-65. doi: 10.1016/j.ahj.2015.06.016. Epub 2015 Jun 26.

PMID:
26385040
30.

[NOAC in everyday clinical practice].

Svensson PJ, Själander A.

Lakartidningen. 2015 Sep 8;112. pii: DH3X. Review. Swedish.

31.

Warfarin persistence among stroke patients with atrial fibrillation.

Björck F, Renlund H, Svensson PJ, Själander A.

Thromb Res. 2015 Oct;136(4):744-8. doi: 10.1016/j.thromres.2015.07.028. Epub 2015 Jul 30.

PMID:
26254195
32.

Warfarin treatment quality is consistently high in both anticoagulation clinics and primary care setting in Sweden.

Björck F, Sandén P, Renlund H, Svensson PJ, Själander A.

Thromb Res. 2015 Aug;136(2):216-20. doi: 10.1016/j.thromres.2015.04.016. Epub 2015 Apr 22.

PMID:
25935649
33.

Second malignancies following treatment of chronic myeloid leukaemia in the tyrosine kinase inhibitor era.

Gunnarsson N, Stenke L, Höglund M, Sandin F, Björkholm M, Dreimane A, Lambe M, Markevärn B, Olsson-Strömberg U, Richter J, Wadenvik H, Wallvik J, Själander A.

Br J Haematol. 2015 Jun;169(5):683-8. doi: 10.1111/bjh.13346. Epub 2015 Mar 27.

PMID:
25817799
34.

Safety and efficacy of well managed warfarin. A report from the Swedish quality register Auricula.

Sjögren V, Grzymala-Lubanski B, Renlund H, Friberg L, Lip GY, Svensson PJ, Själander A.

Thromb Haemost. 2015 Jun;113(6):1370-7. doi: 10.1160/TH14-10-0859. Epub 2015 Feb 26.

PMID:
25716771
35.

Musculoskeletal pain in patients with chronic myeloid leukemia after discontinuation of imatinib: a tyrosine kinase inhibitor withdrawal syndrome?

Richter J, Söderlund S, Lübking A, Dreimane A, Lotfi K, Markevärn B, Själander A, Saussele S, Olsson-Strömberg U, Stenke L.

J Clin Oncol. 2014 Sep 1;32(25):2821-3. doi: 10.1200/JCO.2014.55.6910. Epub 2014 Jul 28. No abstract available.

PMID:
25071107
36.

Thromboembolism, major bleeding and mortality in patients with mechanical heart valves- a population-based cohort study.

Labaf A, Grzymala-Lubanski B, Stagmo M, Lövdahl S, Wieloch M, Själander A, Svensson PJ.

Thromb Res. 2014 Aug;134(2):354-9. doi: 10.1016/j.thromres.2014.06.007. Epub 2014 Jun 12.

PMID:
24985036
37.

Mechanical heart valve prosthesis and warfarin - treatment quality and prognosis.

Grzymala-Lubanski B, Labaf A, Englund E, Svensson PJ, Själander A.

Thromb Res. 2014 May;133(5):795-8. doi: 10.1016/j.thromres.2014.02.031. Epub 2014 Mar 4.

PMID:
24642005
38.

Atrial fibrillation patients do not benefit from acetylsalicylic acid.

Själander S, Själander A, Svensson PJ, Friberg L.

Europace. 2014 May;16(5):631-8. doi: 10.1093/europace/eut333. Epub 2013 Oct 24.

PMID:
24158253
39.

Tyrosine kinase inhibitor usage, treatment outcome, and prognostic scores in CML: report from the population-based Swedish CML registry.

Höglund M, Sandin F, Hellström K, Björeman M, Björkholm M, Brune M, Dreimane A, Ekblom M, Lehmann S, Ljungman P, Malm C, Markevärn B, Myhr-Eriksson K, Ohm L, Olsson-Strömberg U, Själander A, Wadenvik H, Simonsson B, Stenke L, Richter J.

Blood. 2013 Aug 15;122(7):1284-92. doi: 10.1182/blood-2013-04-495598. Epub 2013 Jul 10.

40.

Estimated glomerular filtration rate is associated with major bleeding complications but not thromboembolic events, in anticoagulated patients taking warfarin.

Wieloch M, Jönsson KM, Själander A, Lip GY, Eriksson N, Svensson PJ.

Thromb Res. 2013 Jun;131(6):481-6. doi: 10.1016/j.thromres.2013.01.006. Epub 2013 Jan 23.

PMID:
23351664
41.

Computer aided warfarin dosing in the Swedish national quality registry AuriculA - Algorithmic suggestions are performing better than manually changed doses.

Grzymala-Lubanski B, Själander S, Renlund H, Svensson PJ, Själander A.

Thromb Res. 2013 Feb;131(2):130-4. doi: 10.1016/j.thromres.2012.11.016. Epub 2012 Dec 8.

PMID:
23232091
42.

Computerised assistance for warfarin dosage--effects on treatment quality.

Dimberg I, Grzymala-Lubanski B, Hägerfelth A, Rosenqvist M, Svensson P, Själander A.

Eur J Intern Med. 2012 Dec;23(8):742-4. doi: 10.1016/j.ejim.2012.07.011. Epub 2012 Aug 20.

PMID:
22917757
43.

Low-molecular-weight heparin prophylaxis does not affect mortality in acutely ill medical patients at low risk for venous thromboembolism.

Själander A.

Evid Based Med. 2012 Dec;17(6):e12. doi: 10.1136/ebmed-2012-100631. Epub 2012 Apr 17. No abstract available.

PMID:
22511642
44.

Combination of pegylated IFN-α2b with imatinib increases molecular response rates in patients with low- or intermediate-risk chronic myeloid leukemia.

Simonsson B, Gedde-Dahl T, Markevärn B, Remes K, Stentoft J, Almqvist A, Björeman M, Flogegård M, Koskenvesa P, Lindblom A, Malm C, Mustjoki S, Myhr-Eriksson K, Ohm L, Räsänen A, Sinisalo M, Själander A, Strömberg U, Bjerrum OW, Ehrencrona H, Gruber F, Kairisto V, Olsson K, Sandin F, Nagler A, Nielsen JL, Hjorth-Hansen H, Porkka K; Nordic CML Study Group.

Blood. 2011 Sep 22;118(12):3228-35. doi: 10.1182/blood-2011-02-336685. Epub 2011 Jun 17.

PMID:
21685374
45.

Anticoagulation control in Sweden: reports of time in therapeutic range, major bleeding, and thrombo-embolic complications from the national quality registry AuriculA.

Wieloch M, Själander A, Frykman V, Rosenqvist M, Eriksson N, Svensson PJ.

Eur Heart J. 2011 Sep;32(18):2282-9. doi: 10.1093/eurheartj/ehr134. Epub 2011 May 26.

PMID:
21616951
46.

[Guidelines for anticoagulation in patients with valve prosthesis. More supposition than scientific evidence].

Själander A, Jeppsson A, Svensson PJ.

Lakartidningen. 2010 Sep 29-Oct 5;107(39):2326-8. Review. Swedish. No abstract available.

PMID:
20973249
47.

[Investigation of thrombosis--only when the patient benefits from the results].

Själander A, Missios A, Mulugeta E, Wetterlöv T, Svensson PJ.

Lakartidningen. 2010 Mar 10-16;107(10):679-81. Review. Swedish. No abstract available.

PMID:
20402252
48.

[Prothrombin complex concentrate good in warfarin induced hemorrhage. Quick reversal--plasma should be avoided].

Själander A, Berntorp E, Svensson PJ.

Lakartidningen. 2009 Sep 9-15;106(37):2278, 2280-1. Swedish. No abstract available.

PMID:
19817161
49.

[Thrombocytopenia can be HIT. Heparin treatment can cause low life-threatening thrombocyte levels].

Själander A, Johansson L, Hillarp A, Bergqvist D, Tengborn L, Svensson P.

Lakartidningen. 2009 Mar 4-10;106(10):682-5. Swedish. No abstract available.

PMID:
19418688
50.

[Antithrombotic treatment in atrial fibrillation. Background to new recommendations and therapeutic alternative].

Själander A, Wallentin L, Rosenqvist M, Svensson P.

Lakartidningen. 2008 Sep 10-16;105(37):2478-80. Swedish. No abstract available.

PMID:
19006862

Supplemental Content

Loading ...
Support Center